My Insurance Stopped Covering Wegovy®: What Are Your Options?

If your insurance stopped covering Wegovy®, you generally have four paths: appeal the denial or ask about a formulary exception, pay cash for Wegovy® directly (including, for some patients, Novo Nordisk's own NovoCare self-pay program), ask your clinician whether a different FDA-approved GLP-1 fits your plan's coverage, or ask about compounded semaglutide as a separate, non-equivalent option. None of these guarantee a specific outcome — a US-licensed clinician reviews your history and guides which path, if any, makes sense for you.

Why did my insurance stop covering Wegovy®?

A handful of common reasons, and none of them mean you did anything wrong:

• Formulary changes. Insurers revise their covered-drug lists annually (sometimes mid-year), and anti-obesity medications are a frequent target given their cost to the plan.
• Employer opt-out. Many employer-sponsored plans specifically exclude weight-loss medications, even when the same insurer covers Wegovy® for other employer groups.
• New prior-authorization criteria. A plan may keep covering Wegovy® but add requirements — a minimum BMI, documentation of a supervised diet attempt, or periodic re-authorization — that your existing prescription didn't meet.
• Medicare's statutory exclusion. Medicare is prohibited by law from covering medications prescribed for weight loss, so Medicare does not cover Wegovy® regardless of diagnosis or plan.

What are my options, step by step?

Can I appeal an insurance denial for Wegovy®?

Often, yes — appeals succeed more often than patients expect, especially when the denial is about prior-authorization paperwork rather than a flat plan exclusion. A few steps that help:

1. Get the denial reason in writing. Insurers are required to state why a claim or prior authorization was denied; the reason determines what kind of appeal makes sense.
2. Ask your clinician for a letter of medical necessity. This documents your diagnosis, prior treatment history, and clinical rationale for Wegovy® specifically.
3. Follow your plan's formal appeal process. Every plan has one, usually with a specific deadline and a required form — your insurer's member portal or the denial letter itself will list the steps.
4. Check whether new criteria apply. If the plan added requirements (a BMI threshold, documented diet history, a step-therapy requirement), find out whether you already meet them — sometimes it's a documentation gap, not a true denial.

If a plan excludes weight-loss medications entirely, an appeal on medical-necessity grounds is unlikely to succeed — that's a coverage-design decision, not a clinical judgment call.

What does Wegovy® cost with cash pay?

Two cash-pay paths exist for the same FDA-approved product:

Through a standard pharmacy or a telehealth platform, cash-pay Wegovy® pricing varies by pharmacy — at Pallas it's $599/mo cash-pay, not billed to insurance. Through NovoCare, Novo Nordisk's own self-pay channel, eligible self-pay patients may find a lower-cost path directly from the manufacturer; this article intentionally doesn't quote NovoCare's pricing, since self-pay rates change — see NovoCare directly or our semaglutide cost breakdown for current figures. Either way, the medication itself is the same FDA-approved product — the payment channel changes, not the drug.

Could a different FDA-approved GLP-1 work instead?

Possibly — that's a clinical decision your provider makes with you, not something to decide from a formulary PDF alone. A few things worth knowing:

• Zepbound® and Mounjaro® (tirzepatide, Eli Lilly) are a different molecule from Wegovy®/Ozempic® (semaglutide, Novo Nordisk), approved separately, and may sit on a different formulary tier with your specific plan. See our Wegovy® vs. Zepbound® comparison and semaglutide vs. tirzepatide comparison for how the two differ.
• Ozempic® (also semaglutide) is FDA-approved specifically for type 2 diabetes, not weight management on its own — a clinician would only consider it if that's your diagnosis.
• Switching brands doesn't reset your coverage odds automatically. Some plans exclude the entire anti-obesity drug class regardless of which specific medication you request.

Is compounded semaglutide an option if insurance won't cover Wegovy®?

It's a separate option a clinician may consider — not a substitute for Wegovy®, and not something a lost insurance claim by itself justifies. Compounded semaglutide is prepared per-patient by a US-licensed compounding pharmacy under FDCA §503A, and current FDA guidance requires a documented, patient-specific clinical rationale for that prescription — an intolerance to the FDA-approved formulation, a non-standard dose need, or another documented clinical reason. An insurance denial, price alone, or general preference for the compounded option isn't a sufficient basis on its own.

Compounded medications are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary.

If your clinician determines a compounded preparation is appropriate for you for a documented clinical reason, it's dispensed as its own, separately regulated product — not framed as a like-for-like swap for Wegovy®. For a full breakdown of how the two differ, see compounded vs. brand-name GLP-1 medications and how much compounded semaglutide costs.

Where does Pallas fit?

Pallas dispenses FDA-approved Wegovy® through US-licensed pharmacies on a cash-pay basis, and separately offers compounded semaglutide, prepared by US-licensed compounding pharmacies, when a clinician documents it's the appropriate option for you. Both are cash-pay; insurance isn't billed for either. A licensed partner pharmacy fills and ships whichever prescription your clinician writes, and eligibility for any option is always determined by a US-licensed clinician. Learn more about semaglutide treatment at Pallas.

---

Bottom line: A dropped or denied Wegovy® claim isn't a dead end. Appealing the decision, paying cash (directly or through NovoCare), asking about a different FDA-approved GLP-1, and asking about compounded semaglutide as a separate §503A option are all real paths — none of them guaranteed, and all of them starting with a clinician who reviews your specific history and current coverage.